Close Menu
November 03, 2020

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Genome Webinar

Lead Scientist, Molecular Profiling, NEO New Oncology

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers. While conventional technologies, such as FISH and PCR, allow accurate low-throughput detection (e.g., EML4-ALK fusion), next-generation sequencing-based approaches enable comprehensive and simultaneous identification of various alterations (single nucleotide variants, insertions/deletions, fusions, copy number alterations) and genomic signatures (microsatellite instability, tumor mutational burden).

Compared to conventional technologies, NGS-based approaches overcome the challenge of limited materials and reduce the turnaround time. However, further improvements are still needed due to the complex structure of the genome, including repetitive regions and high GC/AT content.

In this webinar, Dr. Judith Müller-Eisert of NEO New Oncology will discuss a collaboration with Agilent Technologies to develop several hybrid capture-based assays for various tumor entities using the SureSelect XT HS2 chemistry. She will share details of the kit’s performance and discuss its use as a powerful tool for cancer profiling.

For Research Use Only. Not for use in diagnostic procedures.

Sep
24

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.